Cochlear Introduces Osia 3 with Rechargeable Hearing Technology
LONE TREE, Colorado, July 13, 2026 Cochlear Limited, a global leader in implantable hearing solutions, has announced U.S. FDA...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONE TREE, Colorado, July 13, 2026 Cochlear Limited, a global leader in implantable hearing solutions, has announced U.S. FDA...
NEW YORK, NY, April 27, 2026 TytoCare has achieved a major regulatory milestone with the U.S. Food and Drug...
